ZTS / Zoetis Tumbles As Spot's Drugmaker Reports Mixed Earnings, Though Keeps Outlook

While the top- and bottom-line numbers for Zoetis (ZTS) give a sense of how the business performed in the quarter ended September 2023, it could be wo more_horizontal

Kristin Peck, Zoetis CEO, joins 'Squawk on the Street' to discuss her insights into livestock and pet care products, how tied Zoetis' business is to t more_horizontal

Zoetis is an animal health company specializing in the development and manufacturing of veterinary pharmaceuticals and vaccines for both livestock and more_horizontal

Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in more_horizontal

Zoetis Inc., the world's largest provider of animal medicines, vaccines, and diagnostic products, is capitalizing on the growing trend of pet pamperin more_horizontal

Zoetis' (ZTS) revenues are expected to boost the pet care and livestock product sales in the quarters ahead. Disease outbreaks and potential supply ch more_horizontal

Kristin Peck, Zoetis CEO, joins 'Squawk on the Street' to discuss what the company's guidance was largely driven by, the most important aspect of Zoet more_horizontal

Zoetis Inc. (NYSE:ZTS ) Q22023 Earnings Conference Call August 8, 2023 8:30 AM ET Company Participants Steve Frank - Vice President of Investor Relati more_horizontal